Dolutegravir for second-line treatment: Programmatic implications of new evidence

被引：2
作者：
Zhao, Ying [1 ,2 ]
Maartens, Gary [2 ,3 ]
Meintjes, Graeme [1 ,2 ]
机构：
[1] Univ Cape Town, Fac Hlth Sci, Dept Med, Cape Town, South Africa
[2] Univ Cape Town, Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa, Cape Town, South Africa
[3] Univ Cape Town, Dept Med, Div Clin Pharmacol, Cape Town, South Africa
来源：
SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE | 2022年 / 23卷 / 01期
关键词：
LAMIVUDINE; TENOFOVIR;
D O I：
10.4102/sajhivmed.v23i1.1428
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Emergent Resistance to Dolutegravir Among INSTI-Naive Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
    Cevik, Muge
    Orkin, Chloe
    Sax, Paul E.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
  • [2] International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019
    Chammartin, Frederique
    Ostinelli, Cam Ha Dao
    Anastos, Kathryn
    Jaquet, Antoine
    Brazier, Ellen
    Brown, Steven
    Dabis, Francois
    Davies, Mary-Ann
    Duda, Stephany N.
    Malateste, Karen
    Nash, Denis
    Wools-Kaloustian, Kara
    von Groote, Per M.
    Egger, Matthias
    [J]. BMJ OPEN, 2020, 10 (05):
  • [3] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Gallant, JE
    DeJesus, E
    Arribas, JR
    Pozniak, AL
    Gazzard, B
    Campo, RE
    Lu, B
    McColl, D
    Chuck, S
    Enejosa, J
    Toole, JJ
    Cheng, AK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) : 251 - 260
  • [4] Hakim JG, 2018, LANCET INFECT DIS, V18, P47, DOI [10.1016/S1473-3099(17)30630-8, 10.1016/s1473-3099(17)30630-8]
  • [5] Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
    Keene, Claire M.
    Griesel, Rulan
    Zhao, Ying
    Gcwabe, Zimasa
    Sayed, Kaneez
    Hill, Andrew
    Cassidy, Tali
    Ngwenya, Olina
    Jackson, Amanda
    van Zyl, Gert
    Schutz, Charlotte
    Goliath, Rene
    Flowers, Tracy
    Goemaere, Eric
    Wiesner, Lubbe
    Simmons, Bryony
    Maartens, Gary
    Meintjes, Graeme
    [J]. AIDS, 2021, 35 (09) : 1423 - 1432
  • [6] Mulenga LB., 2017, C RETROVIRUSES OPPOR
  • [7] Paton NI, 2022, LANCET HIV, DOI DOI 10.1016/S2352-3018(22)
  • [8] Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa
    Romo, Matthew L.
    Edwards, Jessie K.
    Semeere, Aggrey S.
    Musick, Beverly S.
    Urassa, Mark
    Odhiambo, Francesca
    Diero, Lameck
    Kasozi, Charles
    Murenzi, Gad
    Lelo, Patricia
    Wyka, Katarzyna
    Kelvin, Elizabeth A.
    Sohn, Annette H.
    Wools-Kaloustian, Kara K.
    Nash, Denis
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (04) : 630 - 637
  • [9] Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
    Underwood, Mark
    Horton, Joe
    Nangle, Keith
    Hopking, Judy
    Smith, Kimberly
    Aboud, Michael
    Wynne, Brian
    Sievers, Jorg
    Stewart, Eugene L.
    Wang, Ruolan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
  • [10] World Health Organization, 2021, CONSOLIDATED GUIDELI
1